Dr Nancy Valente | Vice President, Global Product Development, Hematology/Oncology; Head Hematology Development
Genentech

Dr Nancy Valente, Vice President, Global Product Development, Hematology/Oncology; Head Hematology Development, Genentech

Nancy Valente, M.D. is VP, Global Product Development Oncology and Head of Hematology Development at Genentech where she leads the clinical development of hematology medicines. A board certified hematologist and medical oncologist, she is focused on continuing to improve outcomes for people with diseases of the blood, including cancers and hemophilia.   She was recognized by FiercePharma, as a Fierce Women in BioPhama in 2016. 
 
Dr. Valente, who has more than 16 years of industry experience, joined Genentech in 2003. She is responsible for clinical development strategy for an extensive hematology portfolio, with medicines that span diverse mechanisms such as antibodies, antibody drug conjugates, apoptosis, immune therapy, and signaling. She oversees a team of 60 medical directors and clinical scientists located at three global sites in California, England and Switzerland.  During her time at Genentech, she has overseen the development programs for Rituxan, Gazyva, the first medicine with Breakthrough Designation to be approved by the FDA, and more recently Venclexta, a first-in-class pro apoptotic therapy.
 
Previously, Dr. Valente held positions at Coulter Pharmaceutical and Anosys, Inc., leading the Phase I/III development of biologic therapeutics (antibodies and vaccines) for solid tumors and hematological malignancies.
 
Dr. Valente started her career as a practicing oncologist at the University of California San Francisco (UCSF) where she specialized in breast cancer as UCSF faculty. She received her medical degree from the University of Missouri and completed internal medicine training at Oregon Health Sciences University, followed by fellowships in hematology at Stanford University and oncology at UCSF. Dr. Valente has published research in hematology, solid tumors and immunotherapy in leading scientific journals and is an active member of the American Society of Clinical Oncology, the American Association for Cancer Research, and the American Society of Hematology.
 
 

Appearances:



West Coast Day 1 @ 09:45

The evolution of antibody therapy for cancer

  • Progress in the development of antibody drug conjugates,bispecific antibodies, and fusion protein/antibodies
  • Novel approaches in antibody therapy- who is leading the next generation of antibody development?
  • What have been the most successful and least successful antibody therapies? Why?
  • How do we decide what level of toxicity is acceptable? Does this vary across indications?
last published: 22/Nov/18 11:45 GMT

back to speakers

Sign Up for Event Updates

Contact us

To sponsor or exhibit contact:
Oliver Breed
+44 (0)207 092 1156

oliver.breed@terrapinn.com


To speak:
Lauren Sheppard
+44 (0)207 092 1211

lauren.sheppard@terrapinn.com